This Week in Allergy & Immunology — Jun 5, 2026

Welcome to This Week in Allergy & Immunology. This week we're covering 10 notable papers spanning new frontiers in B-cell modulation, refinements in managing atopic and airway diseases, and practical guidance for specific clinical scenarios. Let's dive in.

We begin this week with a deep dive into B-cell modulation and antibody-mediated diseases, an area seeing rapid innovation. In a major phase 3 trial published in The New England Journal of Medicine, researchers evaluated obexelimab for IgG4-related disease [3]. This is a chronic fibroinflammatory condition where glucocorticoids are the mainstay but carry significant toxicity, and relapse is common. Obexelimab is a novel bifunctional monoclonal antibody that inhibits B-cell activity by co-engaging CD19 and Fc-gamma-RIIb, but without causing B-cell depletion. In this double-blind, placebo-controlled trial, 194 patients with active disease were randomized to weekly obexelimab or placebo, with a standardized glucocorticoid taper to discontinuation by week 8. The results were significant: the time to the first disease flare was substantially longer with obexelimab, with flares occurring in about 27% of the obexelimab group compared to nearly 55% of the placebo group. This translated to a hazard ratio of 0.44. Obexelimab also proved superior on all key secondary endpoints, including complete remission at one year and a nearly two-thirds reduction in the cumulative dose of rescue glucocorticoids. While side effects like arthralgias and hypersensitivity were slightly more common, serious adverse events were actually less frequent in the treatment group. This trial provides a powerful new steroid-sparing option for our patients with IgG4-related disease. Providing mechanistic context for B-cell dysregulation, a study in The Journal of Allergy and Clinical Immunology explored the complex interplay of BAFF, its receptors, and B-cell subsets in Common Variable Immunodeficiency, or CVID [10]. Researchers found that patients with CVID complicated by autoimmune cytopenias and lymphoid hyperplasia had an elevated plasma BAFF to TACI ratio. This was associated with an increase in transitional and activated naïve B cells. These expanded B-cell subsets showed increased expression of genes that promote B-cell survival, reduced surface expression of the BAFF receptor, and an increased frequency of autoreactive B-cell receptor clones. This work helps to explain the pathogenic mechanisms behind non-infectious complications in CVID and highlights how a convergence of factors can subvert B-cell tolerance. And finally, pushing the boundaries of what's possible, a report also in The New England Journal of Medicine details the use of CAR T-cell therapy to enable kidney transplantation in two highly sensitized candidates [2]. HLA sensitization is a massive barrier to transplantation. In this phase 1 study, investigators used a dual-targeted CAR T-cell therapy aimed at both CD19 and BCMA to eliminate the cellular sources of preformed anti-HLA antibodies. This desensitization strategy was successful, allowing both patients to undergo kidney transplantation. While this is from a very early safety run-in cohort, it represents a potential paradigm shift for managing the most highly sensitized patients on the transplant waitlist.

Our next theme covers advances in managing common atopic and airway diseases. A comprehensive primer in Nature Reviews Disease Primers provides a state-of-the-art overview of atopic dermatitis [1]. It reaffirms AD as the most common inflammatory skin disease, with a global burden ranking 15th among all non-fatal diseases. The review highlights its deep connections not only to the classic atopic march of food allergy, asthma, and allergic rhinitis, but also to mental health disorders and other immune-mediated conditions like alopecia areata. Importantly, it charts the field's progress from broad immunosuppression to targeted biologics and next-generation small molecules, while appropriately cautioning that global inequity in access to these novel therapies remains a major challenge. Shifting to the airways, we have two papers that speak to the growing role of biologics beyond classic asthma. A review in Current Allergy and Asthma Reports provides a landscape view, summarizing the established efficacy of biologics targeting Type 2 pathways in severe eosinophilic asthma—including agents against IgE, IL-5, IL-4/13, and TSLP [7]. It also looks ahead to emerging therapies for non-Type 2 and steroid-resistant asthma, such as TNF-alpha blockers and JAK-STAT inhibitors. However, a paper in Annals of Allergy, Asthma, & Immunology brings this concept into immediate clinical focus for Chronic Obstructive Pulmonary Disease, or COPD [9]. While COPD has traditionally been seen as a neutrophilic disease, there is mounting evidence for a Type 2 inflammatory endotype in a subset of patients. This review highlights randomized trial data showing that monoclonal antibodies can reduce exacerbations in carefully selected patients with eosinophilic COPD, even those without a history of asthma. This has led to the recent inclusion of dupilumab and mepolizumab in international treatment guidelines for COPD. A key finding is that patients with moderate COPD who have both elevated blood eosinophils and Fractional Exhaled Nitric Oxide, or FeNO, seem to derive the greatest benefit, supporting the idea of earlier intervention in these high-risk individuals. In the realm of food allergy, we have two complementary studies on oral immunotherapy. First, a study in Annals of Allergy, Asthma, & Immunology compared three different office-based egg oral immunotherapy, or OIT, protocols in 96 patients [5]. The protocols were low-dose native egg, high-dose native egg, and baked egg. The study found that the low-dose native egg OIT protocol was the best tolerated, with lower rates of premedication and epinephrine use. Overall, 74% of all participants were able to freely eat baked egg plus at least 3 grams of native egg, and 58% passed a full oral food challenge, allowing them to liberalize egg in their diet. This provides practical evidence that office-based egg OIT is a feasible and effective therapy. But what is the experience like for families? A mixed-methods study in Pediatric Allergy and Immunology explored the parental perspective on early-life OIT for various food allergies [8]. Parents reported high confidence and low anxiety, with excellent adherence rates above 94%. However, focus groups revealed the hidden emotional burden, especially during initiation, and the practical challenges of dose administration. Parents were motivated by the hope of inducing tolerance. They emphasized that professional support and good expectation management were essential. The key message for clinicians is that while eOIT is feasible, it is demanding, and a family-centered approach with robust education and psychosocial support is critical for success.

Our final group of papers touches on specific procedural risks and a look to the future. For clinicians managing patients with Hereditary Angioedema, or HAE, a retrospective study in Annals of Allergy, Asthma, & Immunology provides valuable data for perioperative planning [6]. Analyzing 410 procedures in 58 patients, the researchers confirmed that attack risk follows a clear gradient based on invasiveness. Major surgery carried the highest risk, with attacks occurring in about 35% of cases. In contrast, minimally invasive cosmetic procedures had a risk of less than 2%. Prophylaxis was highly effective; for minor surgeries, no attacks occurred in patients who received prophylaxis, compared to a 13% rate in those who did not. This study strongly supports the use of stratified, risk-based prophylactic protocols tailored to the specific procedure. Finally, looking ahead, a review in the journal Allergy explores the expanding role of Artificial Intelligence in our field [4]. AI is already being used to analyze satellite imagery to model pollutant dispersion, predict environmental exposures, and assess chemical safety. These technologies can help us understand the complex relationships between the exposome—the sum of all exposures over a lifetime—and health outcomes. While the authors caution about limitations and the potential for bias, AI holds immense promise for improving environmental health and safety, managing climate-related crises, and ultimately, facilitating preventative strategies in allergy and immunology.

If you only have time for one paper this week, make it the obexelimab trial for IgG4-related disease in The New England Journal of Medicine [3]. It’s a well-conducted phase 3 study that establishes a new, effective, steroid-sparing treatment with a novel, non-depleting mechanism for a very challenging condition.

Here are the key takeaways from this week in Allergy & Immunology: First, for your patients with active IgG4-related disease, weekly obexelimab represents a new, effective, steroid-sparing option that significantly reduces disease flares by modulating B-cell activity without depletion. Second, in your COPD patients, don't forget to check for a Type 2 inflammatory signature. In those with elevated blood eosinophils and FeNO, biologics like mepolizumab and dupilumab can reduce exacerbations and are now part of treatment guidelines. Third, for motivated families with egg allergy, office-based oral immunotherapy is a viable option. A low-dose native egg protocol appears to have a favorable safety and efficacy profile, but success depends on providing strong family-centered education and psychosocial support. Fourth, when a patient with hereditary angioedema requires a procedure, tailor your prophylaxis to the level of risk. The more invasive the procedure, the higher the risk of an attack, and the more critical prophylaxis becomes. Finally, keep an eye on the rapidly evolving field of B-cell targeted therapies. From mechanistic insights in CVID to groundbreaking applications like CAR-T for transplant desensitization, this area promises to reshape how we manage a wide range of immune-mediated diseases.

That's your roundup for This Week in Allergy & Immunology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.